ProMIS Neurosciences Inc. (PMN:TSX; ARFXF:OTCQB) announced in a news release that Dr. C. Warren Olanow, an expert in neurodegenerative disorders, has joined its scientific advisory board.
The body, comprised of renowned specialists in neurodegenerative disease and experts in neurotoxic, prion-like misfolded proteins, guides development of the company's clinical programs in Parkinson's disease, Alzheimer's disease and amyotrophic lateral sclerosis.
Olanow brings to the board a deep knowledge of and expertise in neurodegeneration, particularly with respect to movement disorders and Parkinson's disease, on which he has written more than 300 papers. His research has revolved around the etiology and pathogenesis of neurodegeneration and experimental therapeutics.
Currently, Olanow is the CEO of CLINTREX, a pharmaceutical advisory firm that designs clinical trials in neurodegenerative disease for the pharmaceutical industry.
Previously, he was a professor in and the chairman of the Department of Neurology at Mount Sinai's School of Medicine and now is a professor emeritus in the same as well as in the Department of Neuroscience.
His long list of accolades, achievements and service include receiving the Lifetime Achievement award from the International Parkinson and Movement Disorder Society.
Olanow earned his medical degree at the University of Toronto and received his neurology training at the Neurological Institute of New York at Columbia University.
Read what other experts are saying about:
Disclosure:
1) Doresa Banning compiled this article for Streetwise Reports LLC and provides services to Streetwise Reports as an independent contractor. She or members of her household own securities of the following companies mentioned in the article: None. She or members of her household are paid by the following companies mentioned in this article: None.
2) The following companies mentioned in this article are billboard sponsors of Streetwise Reports: ProMIS Neurosciences. Click here for important disclosures about sponsor fees.
3) Comments and opinions expressed are those of the specific experts and not of Streetwise Reports or its officers. The information provided above is for informational purposes only and is not a recommendation to buy or sell any security.
4) The article does not constitute investment advice. Each reader is encouraged to consult with his or her individual financial professional and any action a reader takes as a result of information presented here is his or her own responsibility. By opening this page, each reader accepts and agrees to Streetwise Reports' terms of use and full legal disclaimer. This article is not a solicitation for investment. Streetwise Reports does not render general or specific investment advice and the information on Streetwise Reports should not be considered a recommendation to buy or sell any security. Streetwise Reports does not endorse or recommend the business, products, services or securities of any company mentioned on Streetwise Reports.
5) From time to time, Streetwise Reports LLC and its directors, officers, employees or members of their families, as well as persons interviewed for articles and interviews on the site, may have a long or short position in securities mentioned. Directors, officers, employees or members of their immediate families are prohibited from making purchases and/or sales of those securities in the open market or otherwise from the time of the interview or the decision to write an article until three business days after the publication of the interview or article. The foregoing prohibition does not apply to articles that in substance only restate previously published company releases. As of the date of this interview, officers and/or employees of Streetwise Reports LLC (including members of their household) own securities of ProMIS Neurosciences, a company mentioned in this article.
